Immune checkpoint inhibitors (ICIs) have shown limited and inconsistent clinical activity in hormone-receptor-positive (HR+)/HER2-negative HER2− breast cancer, likely due to the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. Here, NR4A1 is linked to neoplasm.